Literature DB >> 23344683

Conservative nephron-sparing treatment of upper-tract tumors.

Paul Smith1, Juliette Mandel, Jay D Raman.   

Abstract

While radical nephroureterectomy represents the gold standard for managing upper-tract urothelial carcinoma, nephron-sparing approaches have increasingly been utilized in the elective setting. Such considerations are accentuated by contemporary studies highlighting sequelae related to chronic kidney disease following nephrectomy. Kidney sparing treatments including segmental ureteral resection and endoscopic ablation may therefore be appropriate in select patients with small, solitary, low-grade upper-tract tumors. Bladder and ipsilateral upper-tract recurrences are frequent after nephron-sparing treatments for UTUC, thereby underscoring the need to maintain strict radiographic and endoscopic surveillance protocols in patients amenable to this rigorous compliance program.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23344683     DOI: 10.1007/s11934-013-0305-1

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  40 in total

Review 1.  Ureteroscopic management of patients with upper tract transitional cell carcinoma.

Authors:  D G Assimos; M C Hall; J H Martin
Journal:  Urol Clin North Am       Date:  2000-11       Impact factor: 2.241

Review 2.  Transitional-cell carcinoma of the renal pelvis: ureteroscopic and percutaneous approach.

Authors:  E N Liatsikos; C Z Dinlenc; R Kapoor; A D Smith
Journal:  J Endourol       Date:  2001-05       Impact factor: 2.942

3.  A comparison of the pathology of transitional cell carcinoma of the bladder and upper urinary tract.

Authors:  Grant D Stewart; Simon V Bariol; Ken M Grigor; David A Tolley; S Alan McNeill
Journal:  BJU Int       Date:  2005-04       Impact factor: 5.588

4.  Significance of urinary cytology in the early detection of transitional cell cancer of the upper urinary tract.

Authors:  H Zincke; J J Aguilo; G M Farrow; D C Utz; A U Khan
Journal:  J Urol       Date:  1976-12       Impact factor: 7.450

5.  Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma.

Authors:  Morgan Rouprêt; Vincent Hupertan; Olivier Traxer; Guillaume Loison; Emmanuel Chartier-Kastler; Pierre Conort; Marc-Olivier Bitker; Bernard Gattegno; François Richard; Olivier Cussenot
Journal:  Urology       Date:  2006-06       Impact factor: 2.649

6.  Third prize: the role of endoscopic nephron-sparing surgery in the management of upper tract urothelial carcinoma.

Authors:  Eliza M Raymundo; Michael E Lipkin; Lionel B Bañez; John G Mancini; Dorit E Zilberman; Glenn M Preminger; Brant A Inman
Journal:  J Endourol       Date:  2011-03       Impact factor: 2.942

7.  Endoscopic management of upper urinary tract transitional cell carcinoma: long-term experience.

Authors:  Siamak Daneshmand; Marcus L Quek; Jeffry L Huffman
Journal:  Cancer       Date:  2003-07-01       Impact factor: 6.860

8.  What is the cost of maintaining a kidney in upper-tract transitional-cell carcinoma? An objective analysis of cost and survival.

Authors:  Raymond W Pak; Eric J Moskowitz; Demetrius H Bagley
Journal:  J Endourol       Date:  2009-03       Impact factor: 2.942

9.  Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery.

Authors:  George N Thalmann; Regula Markwalder; Bernhard Walter; Urs E Studer
Journal:  J Urol       Date:  2002-10       Impact factor: 7.450

10.  Percutaneous management of transitional cell carcinoma of the renal collecting system: 9-year experience.

Authors:  T W Jarrett; P M Sweetser; G H Weiss; A D Smith
Journal:  J Urol       Date:  1995-11       Impact factor: 7.450

View more
  1 in total

1.  Perioperative treatments for resected upper tract urothelial carcinoma: a network meta-analysis.

Authors:  Xiao Yang; Peng Li; Xiaheng Deng; Hongquan Dong; Yidong Cheng; Xiaolei Zhang; Chengdi Yang; Jingyuan Tang; Wenbo Yuan; Xiaoting Xu; Jun Tao; Pengchao Li; Haiwei Yang; Qiang Lu; Min Gu; Zengjun Wang
Journal:  Oncotarget       Date:  2017-01-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.